Long-term disability outcomes in multiple sclerosis
Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. Only limited information is available regarding the long-term impact of the available immunomodualtory therapies. Moreover, the information about the effectiveness of these therapies at various disease stages is lacking. Finally, there is currently no therapy approved for treatment of progressive multiple sclerosis phenotypes.
This project studies disability trajectories during early and advanced stages of mulitple sclerosis. It focuses on the ability of the currently available disease modifying therapies to ameliorate accumulation of irreversible disabilty.
- Dr Tomas Kalincik, project leader
- Mr Nathaniel Lizak, research associate
- MSBase collaborators (117 MS centre in 35 countries)
- NHMRC project grant 108353, Treating progressive MS.
- University of Melbourne Research Fellowship.
- Biogen Fellowship in MS Registries Research.
This research project is available to PhD students to join as part of their thesis.
Please contact the Research Group Leader to discuss your options.
- Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E,… Kalincik T, on behalf of the MSBase Study Group (in press) Defining secondary progressive multiple sclerosis. Brain
- Stewart T, Spelman T, Havrdova E… Kalincik T, on behalf of the MSBase Study Group (in press) Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler
- Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, et al., on behalf of the MSBase Study Group (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138:3287-98